Inconsistencies in reporting of granulomatous infectious diseases associated with infliximab and etanercept.
Thomas F
TF
Schaible
D016907:Adverse Drug Reaction Reporting Systems / Q000458:organization & administration; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000068800:Etanercept; D006105:Granulomatous Disease, Chronic / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects / Q000037:antagonists & inhibitors; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept